Actuate Therapeutics, Inc. Common stock (NASDAQ:ACTU) — Market Cap & Net Worth
Market Cap & Net Worth: Actuate Therapeutics, Inc. Common stock (ACTU)
Actuate Therapeutics, Inc. Common stock (NASDAQ:ACTU) has a market capitalization of $23.13 Million ($23.13 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24725 globally and #5280 in its home market, demonstrating a -21.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Actuate Therapeutics, Inc. Common stock's stock price $1.00 by its total outstanding shares 23243328 (23.24 Million). Also see Actuate Therapeutics, Inc. Common stock assets under control for a full breakdown of the balance sheet.
Actuate Therapeutics, Inc. Common stock Market Cap History: 2024 to 2026
Actuate Therapeutics, Inc. Common stock's market capitalization history from 2024 to 2026. Data shows change from $185.02 Million to $23.13 Million (-64.28% CAGR). Also see Actuate Therapeutics, Inc. Common stock (ACTU) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Actuate Therapeutics, Inc. Common stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #702 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2307 of 3165 |
Weight: Actuate Therapeutics, Inc. Common stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Actuate Therapeutics, Inc. Common stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Actuate Therapeutics, Inc. Common stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ACTU share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ACTU by Market Capitalization
Companies near Actuate Therapeutics, Inc. Common stock in the global market cap rankings as of September 18, 2026. Review ACTU intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Actuate Therapeutics, Inc. Common stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Actuate Therapeutics, Inc. Common stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Actuate Therapeutics, Inc. Common stock's market cap moved from $185.02 Million to $ 23.13 Million, with a yearly change of -64.28%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $23.13 Million | -83.74% |
| 2025 | $142.25 Million | -23.12% |
| 2024 | $185.02 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Actuate Therapeutics, Inc. Common stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.13 Million USD |
| MoneyControl | $23.13 Million USD |
| MarketWatch | $23.13 Million USD |
| marketcap.company | $23.13 Million USD |
| Reuters | $23.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of… Read more